Presentations and webcasts

Register for our Alert Service to be notified whenever we add a presentation to our site.

Title Press Release Powerpoint Webcast
Interim Results 31 Dec 2016 pdf 2012blue pdf 2012blue  
AGM Presentation pdf 2012blue pdf 2012blue  
2015/16 Results Webcast pdf 2012blue pdf 2012blue  
Interim Results 31 Dec 2015 pdf 2012blue pdf 2012blue  
Moxatag Acquisition pdf 2012blue pdf 2012blue  
2014/15 Results Webcast pdf 2012blue pdf 2012blue  
Tuzistra Approval   pdf 2012blue

 

H2 Interim Results Dec 2014  pdf 2012blue  

 

Interim Results June 2014 Webcast    

 

2013 Results Webcast    

 

Interim Results 2013 Webcast    

 

2012 Results Webcast    

 

Interim Results 2012 webcast    

 

Note: To view PDF files, you will need the Adobe Acrobat Reader. This can be downloaded free of charge from the Adobe website.

Latest News

FDA Issues a Complete Response Letter on CCP-08 NDA

Vernalis plc announced today that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for CCP-08. 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch